T B Leeme1,2, M Mine3, K Lechiile1, F Mulenga3, M Mosepele4, T Mphoyakgosi3, C Muthoga1,5, J Ngidi3, B Nkomo6, D Ramaabya6, M Tau6, M W Tenforde5, R Hayes7, J N Jarvis1,2. 1. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. 2. Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. 3. National Health Laboratory, Gaborone, Botswana. 4. Faculty of Medicine, University of Botswana, Gaborone, Botswana. 5. Botswana-UPenn Partnership, Gaborone. 6. Ministry of Health and Wellness, Gaborone, Botswana. 7. Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
Abstract
OBJECTIVES: National guidelines in Botswana recommend baseline CD4 count measurement and both CD4 and HIV viral load (VL) monitoring post-antiretroviral therapy (ART) initiation. We evaluated the utility of CD4 count measurement in Botswana in the era of universal ART. METHODS: CD4 and VL data were analysed for HIV-infected adults undergoing CD4 count measurement in 2015-2017 at the Botswana Harvard HIV-Reference Laboratory. We determined (1) the proportion of individuals with advanced HIV disease (CD4 count < 200 cells/µL) at initial CD4 assessment, (2) the proportion with an initial CD4 count ≥ 200 cells/µL experiencing a subsequent decline in CD4 count to < 200 cells/µL, and (3) the proportion of these immunologically failing individuals who had virological failure. Logistic regression modelling examined factors associated with advanced HIV disease. CD4 count trajectories were assessed using locally weighted scatterplot smoothing (LOWESS) regression. RESULTS: Twenty-five per cent (3571/14 423) of individuals with an initial CD4 assessment during the study period had advanced HIV disease at baseline. Older age [≥ 35 years; adjusted odds ratio (aOR) 1.9; 95% confidence interval (CI) 1.8-2.1] and male sex were associated with advanced HIV disease. Fifty per cent (7163/14 423) of individuals had at least two CD4 counts during the study period. Of those with an initial CD4 count ≥ 200 cells/µL, 4% (180/5061) experienced a decline in CD4 count to < 200 cells/µL; the majority of CD4 count declines were in virologically suppressed individuals and transient. CONCLUSIONS: One-quarter of HIV-positive individuals in Botswana still present with advanced HIV disease, highlighting the importance of baseline CD4 count measurement to identify this at-risk population. Few with a baseline CD4 count ≥ 200 cells/µL experienced a drop below 200 cells/µL, suggesting limited utility for ongoing CD4 monitoring.
OBJECTIVES: National guidelines in Botswana recommend baseline CD4 count measurement and both CD4 and HIV viral load (VL) monitoring post-antiretroviral therapy (ART) initiation. We evaluated the utility of CD4 count measurement in Botswana in the era of universal ART. METHODS: CD4 and VL data were analysed for HIV-infected adults undergoing CD4 count measurement in 2015-2017 at the Botswana Harvard HIV-Reference Laboratory. We determined (1) the proportion of individuals with advanced HIV disease (CD4 count < 200 cells/µL) at initial CD4 assessment, (2) the proportion with an initial CD4 count ≥ 200 cells/µL experiencing a subsequent decline in CD4 count to < 200 cells/µL, and (3) the proportion of these immunologically failing individuals who had virological failure. Logistic regression modelling examined factors associated with advanced HIV disease. CD4 count trajectories were assessed using locally weighted scatterplot smoothing (LOWESS) regression. RESULTS: Twenty-five per cent (3571/14 423) of individuals with an initial CD4 assessment during the study period had advanced HIV disease at baseline. Older age [≥ 35 years; adjusted odds ratio (aOR) 1.9; 95% confidence interval (CI) 1.8-2.1] and male sex were associated with advanced HIV disease. Fifty per cent (7163/14 423) of individuals had at least two CD4 counts during the study period. Of those with an initial CD4 count ≥ 200 cells/µL, 4% (180/5061) experienced a decline in CD4 count to < 200 cells/µL; the majority of CD4 count declines were in virologically suppressed individuals and transient. CONCLUSIONS: One-quarter of HIV-positive individuals in Botswana still present with advanced HIV disease, highlighting the importance of baseline CD4 count measurement to identify this at-risk population. Few with a baseline CD4 count ≥ 200 cells/µL experienced a drop below 200 cells/µL, suggesting limited utility for ongoing CD4 monitoring.
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Gilbert R Kaufmann; Luc Perrin; Guiseppe Pantaleo; Milos Opravil; Hansjakob Furrer; Amalio Telenti; Bernard Hirschel; Bruno Ledergerber; Pietro Vernazza; Enos Bernasconi; Martin Rickenbach; Matthias Egger; Manuel Battegay Journal: Arch Intern Med Date: 2003-10-13
Authors: A S Walker; D Ford; C F Gilks; P Munderi; F Ssali; A Reid; E Katabira; H Grosskurth; P Mugyenyi; J Hakim; J H Darbyshire; D M Gibb; A G Babiker Journal: Lancet Date: 2010-03-27 Impact factor: 79.321
Authors: Sergio Carmona; Jacob Bor; Cornelius Nattey; Brendan Maughan-Brown; Mhairi Maskew; Matthew P Fox; Deborah K Glencross; Nathan Ford; William B MacLeod Journal: Clin Infect Dis Date: 2018-03-04 Impact factor: 20.999
Authors: Keith Jefferis; Ava Avalos; Heston Phillips; Mpho Mmelesi; Dinah Ramaabya; Bornapate Nkomo; Charles Muthoga; Joseph N Jarvis; Siphiwe Ratladi; Robert Selato; John Stover Journal: South Afr J HIV Med Date: 2021-10-15 Impact factor: 2.744
Authors: Joseph N Jarvis; David S Lawrence; David B Meya; Enock Kagimu; John Kasibante; Edward Mpoza; Morris K Rutakingirwa; Kenneth Ssebambulidde; Lillian Tugume; Joshua Rhein; David R Boulware; Henry C Mwandumba; Melanie Moyo; Henry Mzinganjira; Cecilia Kanyama; Mina C Hosseinipour; Chimwemwe Chawinga; Graeme Meintjes; Charlotte Schutz; Kyla Comins; Achita Singh; Conrad Muzoora; Samuel Jjunju; Edwin Nuwagira; Mosepele Mosepele; Tshepo Leeme; Keatlaretse Siamisang; Chiratidzo E Ndhlovu; Admire Hlupeni; Constantine Mutata; Erik van Widenfelt; Tao Chen; Duolao Wang; William Hope; Timothée Boyer-Chammard; Angela Loyse; Síle F Molloy; Nabila Youssouf; Olivier Lortholary; David G Lalloo; Shabbar Jaffar; Thomas S Harrison Journal: N Engl J Med Date: 2022-03-24 Impact factor: 176.079
Authors: David B Meya; Lillian Tugume; Vennie Nabitaka; Proscovia Namuwenge; Sam Phiri; Rita Oladele; Bilkisu Jibrin; Mojisola Mobolaji-Bello; Cecilia Kanyama; Werner Maokola; Sayoki Mfinanga; Cordelia Katureebe; Ikechukwu Amamilo; Brian Ngwatu; Joseph N Jarvis; Thomas S Harrison; Amir Shroufi; Radha Rajasingham; David Boulware; Nelesh P Govender; Angela Loyse Journal: South Afr J HIV Med Date: 2021-08-10 Impact factor: 2.744